Molecular study of inflammation in kidney transplants
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at molecular changes in kidney transplants that have microvascular inflammation (a type of injury). It aims to better understand why some transplants get this inflammation, which could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) who has received a kidney transplant.
- You have had at least one kidney biopsy after your transplant.
- Your biopsy was assessed using the Banff 2022 scoring system.
- Your biopsy was adequate (not too small or damaged).
- Your biopsy did not show signs of blood flow-reperfusion injury.
- You did not have a combined or non-kidney solid organ transplant before this kidney transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genes in the kidney change when the body might be rejecting the transplant. By studying these genes, doctors hope to find better ways to detect kidney rejection early and help keep the kidney healthy longer.
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
This study looks at how memory B cells (a type of immune cell) relate to antibodies against HLA in people waiting for a kidney transplant. It aims to better understand immune responses, which could help improve transplant matching and outcomes.
This study looks at how the immune system reacts in kidney transplant patients who may be experiencing rejection. It aims to better understand and improve treatment for transplant rejection.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Hear when a new Kidney Rejection Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.